Asset profile
SDK001
Small molecule
Evidence outlook · lead readout
NCT06882031 · Acute Promyelocytic Leukemia (APL)
The completed lead evidence is positive, with design limits that temper confidence — see the rationale below for exactly which.
NCT06882031: Treatment order was randomized and every participant received both the oral and intravenous formulations of the same active drug for direct comparison, but the study is open-label, very small, and measures only drug blood levels rather than a clinical outcome.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.